Drug Trial Radar · NCT05327803
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
177
Actual
Start
May 20, 2022
Primary completion
Dec 18, 2024
Study completion Dec 18, 2024
Sponsor
- Lead sponsor
- AN2 Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).
Conditions
- MAC Lung Disease
- Treatment Refractory MAC Lung Disease
Interventions
EpetraboroleDrug
500 mg taken orally QD
PlaceboDrug
Placebo taken orally QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of EpetraboroleTime frame: Baseline to Month 16
- Phase 2: Percentage of Participants Achieving Clinical ResponseTime frame: Baseline to Month 6
- Phase 3: Percentage of Participants Achieving Clinical ResponseTime frame: Baseline to Month 6
Locations
91 sites in 4 countries. Site status is shown where the registry gives one.
423032
Birmingham, Alabama
423037
Tucson, Arizona
423070
Sacramento, California
423069
San Francisco, California
423006
Stanford, California
423068
Washington D.C., District of Columbia
423075
Bay Pines, Florida
423018
DeLand, Florida
423034
Kissimmee, Florida
423033
Tampa, Florida
423054
Tampa, Florida
423047
Tampa, Florida
423038
Vero Beach, Florida
423027
Atlanta, Georgia
423076
Indianapolis, Indiana
423029
Iowa City, Iowa
423015
Kansas City, Kansas
423063
Wichita, Kansas
423065
Jefferson, Louisiana
423042
New Orleans, Louisiana
423060
Baltimore, Maryland
423003
Baltimore, Maryland
423074
Boston, Massachusetts
423061
Boston, Massachusetts
423078
Ann Arbor, Michigan
423031
Rochester, Minnesota
423008
St Louis, Missouri
423004
Omaha, Nebraska
423009
Lebanon, New Hampshire
423024
Manhasset, New York
423014
New York, New York
423013
New York, New York
423071
Chapel Hill, North Carolina
423072
Charlotte, North Carolina
423017
Durham, North Carolina
423039
Winston-Salem, North Carolina
423079
Cleveland, Ohio
423082
Oklahoma City, Oklahoma
423007
Portland, Oregon
423002
Philadelphia, Pennsylvania
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.